BioDelivery Sciences announced that Onsolis (fentanyl buccal soluble film) will be made available by Meda next week for the management of breakthrough pain in patients ≥18 years of age with cancer who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

Onsolis is a C-II controlled substance and will be available in 200mcg, 400mcg, 600mcg, 800mcg, and 1600mcg dosage strengths.

For more information call (877) 466-7654 or visit www.onsolisfocus.com.